Long-term administration of oral XXXX in @entity195 .

@entity2607 @entity1 @entity195
Minimal short-term benefits with oral @entity2607 have been reported in @entity195 . We examined long-term oral @entity2607 therapy in 14 @entity1 with probable @entity195 in an extended double-blind crossover trial in which they received @entity2607 for five intervals of 4 to 6 weeks in length and placebo for one interval determined at random. At each interval a Selective Reminding Test was administered and three indexes were examined: total recall, long-term recall, and intrusions. As a group, @entity1 ' memory test scores were significantly better during the drug period. Two @entity1 who previously had performed worse on drug than on placebo in a short-term trial continued to do so. Nine of the remaining 12 @entity1 performed better on two or more measures on @entity2607 compared with placebo. In some cases scores improved up to 50% over placebo values. This improvement was not predicted by response to medication in the earlier short-term trial. Seven @entity1 completed an additional six-interval crossover trial. All but one continued to have improved performance with oral @entity2607 and, in grouped data, memory measures remained significantly improved. These results suggest that long-term administration of @entity2607 in @entity195 may be more effective than short-term. This benefit can be sustained for up to a year in some @entity1 .
